Drugs / Acetylsalicyclic acid
Acetylsalicyclic acid
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT07012629 | Nov 2025 → Sep 2031 expected | MRI defined brain infarct | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT01420094 | Jun → Sep 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01122602 | Apr → Jul 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00335452 | Jun 2006 → Sep 2009 | acute coronary syndrome, intermediate coronary syndrome | Sanofi | Completed | Mixed |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04142125 Background | Feb 2020 → Sep 2023 | intracranial arterial disease, ischemic stroke | Population Health Research Institute | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-02-18 | Bayer | Results New Research Highlights the Role of Aspirin and Advanced Ultrasound Techniques in Cardiovascular Health bayer.com ↗
It highlights that while recent guidelines have downgraded the routine use of aspirin for primary prevention, there remains a subset of asymptomatic patients with high CV risk who may benefit from aspirin therapy. |
| 2022-05-23 | Bayer | Results Two large Xarelto™ studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease bayer.com ↗
Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) |
| 2021-08-24 | Bayer | Regulatory U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin bayer.com ↗
The U.S. Food and Drug Administration (FDA) has approved an expansion of the peripheral artery disease (PAD) indication for the Xarelto™ (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. |
| 2020-03-28 | Bayer | Results Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularization bayer.com ↗
The risk of acute limb ischemia was significantly reduced by 33% in comparison to aspirin alone. |
| 2017-08-27 | Bayer | Results Bayer’s Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% bayer.com ↗
The benefit shown in the combined efficacy endpoint, major adverse cardiovascular events (MACE), for rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily was mainly driven by a significant reduction of stroke (42%) and CV death (22%). |
| 2011-02-10 | Bristol-Myers Squibb | Results New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin in Reducing Stroke and Systemic Embolism in Patients with Atrial Fibrillation Unsuitable for Warfarin Therapy bms.com ↗
The study results also showed that apixaban demonstrated superiority for its secondary efficacy endpoint in reducing the composite of stroke, systemic embolism, myocardial infarction or vascular death for patients with AF when compared with aspirin. |
| 2010-06-10 | Bristol-Myers Squibb | Results AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy bms.com ↗
This interim analysis also demonstrated an acceptable safety profile for apixaban compared to aspirin. |
| 2009-03-31 | Bristol-Myers Squibb | Results Plavix(®) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants bms.com ↗
The greatest benefit was seen in the reduction of stroke, by 28% (2.4% vs. 3.3% per year, p < 0.001), which is the primary goal of physicians treating patients with atrial fibrillation. |
All press releases naming this drug 9 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetylsalicyclic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01122602 ↗ |
| Known as | ASA | “Drug: acetylsalicyclic acid (ASA)” NCT00335452 ↗1“acetylsalicyclic acid (ASA)” NCT07012629 ↗ |
| Known as | Aspirin | “Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)” NCT01122602 ↗ |
| Known as | BAY1019036 | “Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)” NCT01420094 ↗1“Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)” NCT01122602 ↗ |
| Known as | BAYE4465 | “Acetylsalicyclic acid (Aspirin, BAYE4465)” NCT01122602 ↗ |
| Known as | Fast acting Aspirin | “Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)” NCT01122602 ↗ |
| Known as | Fast release Aspirin | “Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)” NCT01420094 ↗ |
| Route | Oral | “a single, oral dose of fast release aspirin tablets” NCT01122602 ↗ |